Shots:

• MorphoSys to receive $750M upfront- an equity investment of $150M in ADS of MorphoSys- up to 1.1B milestones and royalties on sales of Tafasitamab (Ex- US). The companies will jointly commercialize Tafasitamab in the US with equal profit & loss sharing  
• Incyte will hold exclusive commercialization rights of the product outside the US and will lead the commercialization strategy and book all revenues from sales of Tafasitamab outside the US. Additionally- the companies will share development cost in global and US-based studies @ 55% (Incyte) to 45% (MorphoSys) while Incyte will be wholly responsible for the product development (Ex- the US)
• Tafasitamab is an investigational humanized Fc-engineered mAb targeting CD19 with the expected FDA’s approval and MAA submission to the EMA of its combination therapy with Lenalidomide for r/r DLBCL in mid- 2020. The companies will codevelop the therapy for DLBCL- FL- MZL and CLL

Click here to­ read full press release/ article | Ref: Morphosys | Image: The Street